Key result
Symptomatic Brugada syndrome is linked to ~3.4-fold higher risk of new-onset depression or anxiety.
Why the study?
Reduced psychological health is linked to adverse outcomes and mortality, but whether a Brugada syndrome diagnosis and symptomatic presentation increase the risk of new-onset depression, anxiety, and all-cause mortality was unknown.
Does symptomatic disease presentation increase the risk of new-onset depression or anxiety in patients with Brugada syndrome?
Cohort (n=223)
Yes
Does symptomatic disease presentation increase the risk of new-onset depression or anxiety in patients with Brugada syndrome?
Symptomatic Brugada syndrome is a significant risk factor for the development of clinical depression and anxiety, highlighting a need for psychological screening to mitigate the risk of receiving contraindicated psychotropic medications.
Symptomatic Brugada syndrome may warrant psychological monitoring; leaves open whether screening improves outcomes.
AIMS: Reduced psychological health is associated with adverse patient outcomes and higher mortality. We aimed to examine if a Brugada syndrome (BrS) diagnosis and symptomatic disease presentation were associated with an increased risk of new-onset depression or anxiety and all-cause mortality. METHODS AND RESULTS: All Danish patients diagnosed with BrS (2006-2018) with no history of psychiatric disease and available for ≥6 months follow-up were identified using nationwide registries and followed for up to 5 years after diagnosis. The development of clinical depression or anxiety was evaluated using the prescription of medication and diagnosis codes. Factors associated with developing new-onset depression or anxiety were determined using a multivariate Cox proportional hazards regression model. Disease manifestation was categorized as symptomatic (aborted cardiac arrest, ventricular tachycardia, or syncope) or asymptomatic/unspecified at diagnosis. A total of 223 patients with BrS and no history of psychiatric disease were identified (72.6% male, median age at diagnosis 46 years, 45.3% symptomatic). Of these, 15.7% (35/223) developed new-onset depression or anxiety after BrS diagnosis (median follow-up 5.0 years). A greater proportion of symptomatic patients developed new-onset depression or anxiety compared with asymptomatic patients [21/101 (20.8%) and 14/122 (11.5%), respectively, P = 0.08]. Symptomatic disease presentation (HR 3.43, 1.46-8.05) and older age (lower vs. upper tertile: HR 4.41, 1.42-13.63) were significantly associated with new-onset depression or anxiety. All-cause mortality in this group of patients treated according to guidelines was low (n = 4, 1.8%); however, 3/4 developed depression or anxiety before death. CONCLUSION: Approximately, one-sixth of patients with BrS developed new-onset depression or anxiety following a diagnosis of BrS. Symptomatic BrS disease manifestation was significantly associated with new-onset depression or anxiety.
No takes yet. Share an insight, caveat, or question.
Jespersen et al. (2023) conducted a cohort in Brugada syndrome (n=223). Symptomatic disease manifestation vs. Asymptomatic or unspecified disease manifestation was evaluated on New-onset depression or anxiety (HR 3.43, 95% CI 1.46-8.05, p=0.08). Symptomatic Brugada syndrome disease manifestation was significantly associated with an increased risk of new-onset depression or anxiety compared to asymptomatic manifestation (HR 3.43).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: